microRNAs and NKT cell development and function

microRNA 和 NKT 细胞的发育和功能

基本信息

  • 批准号:
    9241970
  • 负责人:
  • 金额:
    $ 37.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-10 至 2021-02-28
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Natural killer T (NKT) cells are an evolutionarily conserved subset of T cells that are developmentally and functionally distinct from conventional T cells. The ability to quickly secrete large quantities of a variety of cytokines upon activation enables NKT cells to be potent regulators of diverse immune responses. The deficiencies in NKT cell number and function have been linked to the development of many diseases. However, a significant gap remains in our understanding of how the development and function of NKT cells are precisely regulated. MicroRNAs (miRNAs), a recently discovered class of evolutionarily conserved small non-coding RNAs, negatively regulate the expression of protein-coding genes and thereby control essential biological functions and contribute to the development of many diseases. We were the first to report that the deletion of Dicer (a key enzyme for miRNA biogenesis) during hematopoiesis results in a significantly reduced NKT cell number and impaired NKT cell maturation and function, without alternating conventional T cell development in the thymus, suggesting that miRNAs are required for NKT cells. Our long-term goal is to understand how miRNAs regulate NKT cell development and function. While more than 1000 experimentally reported miRNAs, very few specific miRNAs are linked to NKT cells so far. Our objective here is to define specific miRNAs and their targets that regulate NKT cell development and function. Using miRNA arrays, we recently identified dynamic expression of miRNAs, including miR-155, and miR-17-92 cluster, during NKT cell development and activation. These findings plus our recent other reports lead to our central hypothesis that the dynamically expressed miRNAs serve as critical regulators controlling NKT cell development and function through fine-tuning specific target genes. Here we will further test this hypothesis t investigate how dynamic expression of miR-155 and miR-17-92 regulate NKT cell development and function using specific miRNA mutant mice with the gain or loss of miRNA function. The results from proposed studies may not only illuminate the new immunological and molecular mechanisms underlying NKT cell development, but may also facilitate the development of new and more efficient intervention strategies for autoimmune diseases, infection, and cancer based on the NKT cell therapy.
 描述(由申请人提供):自然杀伤T(NKT)细胞是一种进化上保守的T细胞亚群,在发育和功能上与常规T细胞不同。在活化后快速分泌大量多种细胞因子的能力使NKT细胞成为多种免疫应答的有效调节剂。NKT细胞数量和功能的缺陷与许多疾病的发展有关。然而,我们对NKT细胞的发育和功能如何精确调控的理解仍然存在重大差距。microRNAs(miRNAs)是近年来发现的一类进化上保守的非编码小RNA,通过负调控蛋白质编码基因的表达,从而控制重要的生物学功能,并与多种疾病的发生发展密切相关。我们是第一个报道造血过程中Dicer(miRNA生物合成的关键酶)的缺失导致NKT细胞数量显著减少,NKT细胞成熟和功能受损,而不会改变胸腺中的常规T细胞发育,这表明miRNA是NKT细胞所需的。我们的长期目标是了解miRNAs如何调节NKT细胞的发育和功能。虽然有超过1000种实验报道的miRNA,但到目前为止,很少有特定的miRNA与NKT细胞相关。我们的目标是确定特定的miRNAs及其调控NKT细胞发育和功能的靶点。利用miRNA阵列,我们最近确定了在NKT细胞发育和活化过程中miRNA的动态表达,包括miR-155和miR-17-92簇。这些发现加上我们最近的其他报告导致我们的中心假设,即动态表达的miRNAs通过微调特定的靶基因作为控制NKT细胞发育和功能的关键调节因子。在此,我们将进一步验证这一假设,以研究miR-155和miR-17-92的动态表达如何调节NKT细胞的发育和功能,使用特定的miRNA突变小鼠与miRNA功能的获得或丧失。从拟议的研究结果可能不仅阐明了新的免疫和分子机制的NKT细胞的发展,但也可能促进新的和更有效的干预策略的发展,自身免疫性疾病,感染和癌症的基础上NKT细胞治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

QING-SHENG MI其他文献

QING-SHENG MI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('QING-SHENG MI', 18)}}的其他基金

Decoding TGF-beta signaling pathways in skin langerhans cells
解码皮肤朗格汉斯细胞中的 TGF-β 信号通路
  • 批准号:
    10541915
  • 财政年份:
    2022
  • 资助金额:
    $ 37.42万
  • 项目类别:
Roles of HDAC3 in Epidermal Langerhans Cell Ontogeny and Function
HDAC3 在表皮朗格汉斯细胞个体发育和功能中的作用
  • 批准号:
    9888305
  • 财政年份:
    2016
  • 资助金额:
    $ 37.42万
  • 项目类别:
Roles of HDAC3 in Epidermal Langerhans Cell Ontogeny and Function
HDAC3 在表皮朗格汉斯细胞个体发育和功能中的作用
  • 批准号:
    9222709
  • 财政年份:
    2016
  • 资助金额:
    $ 37.42万
  • 项目类别:
Serum miRNA Biomarkers of Islet Autoimmunity
胰岛自身免疫的血清 miRNA 生物标志物
  • 批准号:
    9080976
  • 财政年份:
    2016
  • 资助金额:
    $ 37.42万
  • 项目类别:
Serum miRNA Biomarkers of Islet Autoimmunity
胰岛自身免疫的血清 miRNA 生物标志物
  • 批准号:
    9248240
  • 财政年份:
    2016
  • 资助金额:
    $ 37.42万
  • 项目类别:
Roles of HDAC3 in epidermal Langerhans cell ontogeny and function
HDAC3 在表皮朗格汉斯细胞个体发育和功能中的作用
  • 批准号:
    9082306
  • 财政年份:
    2016
  • 资助金额:
    $ 37.42万
  • 项目类别:
microRNAs and NKT cell development and function
microRNA 和 NKT 细胞的发育和功能
  • 批准号:
    9098864
  • 财政年份:
    2015
  • 资助金额:
    $ 37.42万
  • 项目类别:
microRNA as biomarkers for the response to immunotherapy in melanoma
microRNA 作为黑色素瘤免疫治疗反应的生物标志物
  • 批准号:
    8383931
  • 财政年份:
    2012
  • 资助金额:
    $ 37.42万
  • 项目类别:
microRNA as biomarkers for the response to immunotherapy in melanoma
microRNA 作为黑色素瘤免疫治疗反应的生物标志物
  • 批准号:
    8549182
  • 财政年份:
    2012
  • 资助金额:
    $ 37.42万
  • 项目类别:
miRNAs and epidermal langerhans cell development and function
miRNA 和表皮朗格汉斯细胞的发育和功能
  • 批准号:
    7979036
  • 财政年份:
    2010
  • 资助金额:
    $ 37.42万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
    Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
  • 批准号:
    23K14742
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
  • 批准号:
    10864719
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
  • 批准号:
    10586562
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
  • 批准号:
    23K06589
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
  • 批准号:
    10623380
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
  • 批准号:
    10735148
  • 财政年份:
    2023
  • 资助金额:
    $ 37.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了